Pfizer launches Sickle Cell Advocacy and Leadership Empowerment Grants Program (US)

The focus areas for this grant include initiatives that evaluate community programs that expand access to care, especially for those in underserved and rural communities, novel advocacy initiatives that raise awareness about SCD-related challenges and unmet healthcare needs, and monitoring data systems that identify healthcare gaps that support advocacy and drive policy change.

Sickle Cell Disease continues to be one of the most overlooked and misunderstood conditions, affecting over 100,000 people in the United States. Many individuals with SCD face lifelong challenges due to stigma, disparities in healthcare, shortage of specialists, and limited access to treatment centers. Despite legislative and state-level progress in recent years to expand Care and research, significant barriers remain. Through the SCALE initiative, Pfizer aims to collaborate with partners to improve the quality of life for patients while creating long-term policy impact.

Applicants must address one or more of the outlined grant categories: Assessment & Analysis, which focuses on improving and sustaining care by addressing social determinants and rural initiatives; Policy & Advocacy, which strengthens community empowerment and policy influence; and Data Collection/Surveillance, which targets evidence generation and system-level identification of care gaps to support advocacy efforts.

To be eligible, applicants must demonstrate alignment with at least one grant category, a measurable impact with clear outcomes, relevance to short- or long-term policy goals, and the capacity to deliver quality programs with an advocacy plan.

Pfizer will award a total of 150,000 USD in accelerator grants, offering funding that supports the development and scaling of health solutions and services to improve outcomes in SCD and drive policy change.

For more information, visit Pfizer.